Application of nanostructured lipid carriers: The prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway

DARU, Journal of Pharmaceutical Sciences

Volumn 25, Issue 1, 2017, Pages

  Hassanzadeh, Parichehr ^a   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a   Dehpour, Ahmad Reza ^b   Azhdarzadeh, Morteza ^a   Dinarvand, Meshkat ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ischemic stroke; Nanostructured lipid carriers; PC12 cells; Phosphoinositide 3 kinase; Rat; Sesamol

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CATALASE; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; PHENOL DERIVATIVE; SESAMOL; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; ANTIOXIDANT; LIPID; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CELL DAMAGE; CELL VIABILITY; CEREBROVASCULAR ACCIDENT; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DIFFERENTIAL SCANNING CALORIMETRY; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PC12 CELL LINE; PI3K SIGNALING; RAT; REOXYGENATION; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; ANIMAL; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; METABOLISM; PARTICLE SIZE;

ANIMALS; ANTIOXIDANTS; BENZODIOXOLES; BRAIN ISCHEMIA; CELL SURVIVAL; DISEASE MODELS, ANIMAL; LIPIDS; MALE; NANOSTRUCTURES; PARTICLE SIZE; PC12 CELLS; PHENOLS; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; SIGNAL TRANSDUCTION; STROKE;

EID: 85038895013     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/s40199-017-0191-z     Document Type: Article

References (72)

1. Klijn CJ, Hankey GJ. Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European stroke initiative. Lancet Neurol. 2003;2:698-701.
2. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181-98.
3. Serteser M, Ozben T, Gumuslu S, Balkan S, Balkan E. The effects of NMDA receptor antagonist MK-801 on lipid peroxidation during focal cerebral ischemia in rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 2002;26:871-7.
4. Xu L, Sun J, Lu R, Ji Q, Xu JG. Effect of glutamate on inflammatory responses of intestine and brain after focal cerebral ischemia. World J Gastroenterol. 2005;11:733-6.
5. Chen H, Yoshioka H, Kim GS, Jung JE, Okami N, Sakata H, et al. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal. 2011;14:1505-17.
6. Wu XL, Liou CJ, Li ZY, Lai XY, Fang LW, Huang WC. Sesamol suppresses the inflammatory response by inhibiting NF-κB/MAPK activation and upregulating AMP kinase signaling in RAW 264.7 macrophages. Inflamm Res. 2015;64:577-88.
7. Kumar P, Kalonia H, Kumar A. Protective effect of sesamol against 3-nitropropionic acid-induced cognitive dysfunction and altered glutathione redox balance in rats. Basic Clin Pharmacol Toxicol. 2010;107:577-82.
8. Sharma S, Kaur IP. Development and evaluation of sesamol as an antiaging agent. Int J Dermatol. 2006;45:200-8.
9. Kumar B, Kuhad A, Chopra K. Neuropharmacological effect of sesamol in unpredictable chronic mild stress model of depression: behavioral and biochemical evidences. Psychopharmacology. 2011;214:819-28.
10. Changa CC, Luc WJ, Chiang CW, Jayakumarc T, Ong ET, Hsiaoc G, et al. Potent antiplatelet activity of sesamol in an in vitro and in vivo model: pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase. J Nutr Biochem. 2010;21:1214-21.
11. Hassanzadeh P, Hassanzadeh A. Implication of NGF and endocannabinoid signalling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential. Psychopharmacology. 2013;229:571-8.
12. Hassanzadeh P, Arbabi E, Rostami F. The ameliorative effects of sesamol against seizures, cognitive impairment and oxidative stress in the experimental model of epilepsy. Iran J Basic Med Sci. 2014;17:100-7.
13. Ahmad S, Yousuf S, Ishrat T, Khan MB, Bhatia K, Fazli IS, et al. Effect of dietary sesame oil as antioxidant on brain hippocampus of rat in focal cerebral ischemia. Life Sci. 2005;79:1921-8.
14. Jan KC, Ho CT, Hwang LS. Bioavailability and tissue distribution of sesamol in rat. J Agric Food Chem. 2008;56:7032-7.
15. Geetha T, Singh N, Deol PK, Kaur IP. Biopharmaceutical profiling of sesamol: physiochemical characterization, gastrointestinal permeability and pharmacokinetic evaluation. RSC Adv. 2015;5:4083-91.
16. Hassanzadeh P. New perspectives in biosensor technology. Gastroenterol Hepatol Bed Bench. 2010;3:105-7.
17. Hassanzadeh P, Fullwood I, Sothi S, Aldulaimi D. Cancer nanotechnology. Gastroenterol Hepatol Bed Bench. 2011;4:63-9.
18. Hassanzadeh P. Nanopharmaceurticals: innovative theranostics for the neurological disorders. Biomed Rev. 2014;25:25-34.
19. Hassanzadeh P, Arbabi E, Rostami F, Atyabi F, Dinarvand R. Carbon nanotubes prolong the regulatory action of nerve growth factor on the endocannabinoid signaling. Physiol Pharmacol. 2015;19:167-76.
20. Hassanzadeh P, Arbabi P, Atyabi F, Dinarvand R. Carbon nanotube-anandamide complex exhibits sustained protective effects in an in vitro model of stroke. Physiol Pharmacol. 2016;20:12-23.
21. Hassanzadeh P, Arbabi P, Atyabi F, Dinarvand R. Application of carbon nanotubes as the carriers of the cannabinoid, 2-arachidonoylglycerol: towards a novel treatment strategy in colitis. Life Sci. 2017;179:66-72.
22. Hassanzadeh P, Arbabi P, Atyabi F, Dinarvand R. Nerve growth factor-carbon nanotube complex exerts prolonged protective effects in an in vitro model of ischemic stroke. Life Sci. 2017;179:15-22.
23. Hassanzadeh P, Atyabi F, Dinarvand R. Application of carbon nanotubes for controlled release of growth factors or endocannabinoids: a breakthrough in biomedicine. Biomed Rev. 2016;27:19-27.
24. Kim D, Chun BG, Kim YK, Lee YH, Park CS, Jeon I, et al. In vivo tracking of human mesenchymal stem cells in experimental stroke. Cell Transplant. 2008;16:1007-12.
25. Marsh JN, Hu G, Scot MJ, Zhang H, Goette MJ, Gaffney PJ, et al. A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke. Int J Nanomedicine. 2012;7:5137-49.
26. Ghosh A, Sarkar S, Mandal AK, Das N. Neuroprotective role of nanoencapsulated quercetin in combating ischemia-reperfusion induced neuronal damage in young and aged rats. PLoS One. 2013;8:e57735.
27. Müller RH. Lipid nanoparticles: recent advances. Adv Drug Deliv Rev. 2007;59:375-6.
28. Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14:458-62.
29. Freitas C, Müller RH. Correlation between long-term stability of solid lipid nanoparticles (SLNs) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999;47:125-32.
30. Li F, Wang WYL, He H, Yang J, Tang X. The efficacy and safety of bufadienolides loaded nanostructured lipid carriers. Int J Pharm. 2010;393:203-11.
31. Kumbhar DD, Pokharkar VB. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations. Colloids Surf A Physicochem Eng Asp. 2013;416:32-42.
32. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-7.
33. Mullonkal CJ, Toledo-Pereyra LH. Akt in ischemia and reperfusion. J Investig Surg. 2007;20:195-203.
34. Beloqui A, Solinís MÁ, Gascón AR, del Pozo-Rodríguez A, des Rieux A, Préat V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166:115-23.
35. Yang R, Zhang S, Kong D, Gao X, Zhao Y, Wang Z. Biodegradable polymercurcumin conjugate micelles enhance the loading and delivery of low potency curcumin. Pharm Res. 2012;29:3512e25.
36. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev. 2007;54:34-66.
37. Larsen EC, Hatcher JF, Adibhatla RM. Effect of tricyclodecan-9-yl potassium xanthate (D609) on phospholipid metabolism and cell death during oxygen-glucose deprivation in PC12 cells. Neuroscience. 2007;146:946-61.
38. Koha SH, Kwon H, Parka KH, Ko JK, Kim JH, et al. Protective effect of diallyl disulfide on oxidative stress-injured neuronally differentiated PC12 cells. Mol Brain Res. 2005;133:176-86.
39. Zakharova IO, Sokolova TV, Bayunova LV, Vlasova YA. α-Tocopherol at nanomolar concentration protects PC12 cells from hydrogen peroxide-induced death and modulates protein kinase activities. Int J Mol Sci. 2012;13:11543-68.
40. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47:936-41.
41. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115:61-9.
42. Zhao J, Bai Y, Zhang C, Zhang X, Zhang YX, Chen J, et al. Cinepazide maleate protects PC12 cells against oxygen-glucose deprivation-induced injury. Neurol Sci. 2014;35:875-81.
43. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
44. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-8.
45. Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR. Bromobenze induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzenoxide as the hepatotoxic intermediate. Pharmacology. 1974;11:151-69.
46. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Ind J Biochem Biophys. 1984;21:130-2.
47. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-6.
48. Zhaoa C, Fana T, Yanga Y, Wua M, Li L, Zhoua Z, et al. Preparation, macrophages targeting delivery and anti-inflammatory study of pentapeptide grafted nanostructured lipid carriers. Int J Pharm. 2013;450:11-20.
49. Wang MT, Jin Y, Yang YX, Zhao CY, Yang HY, Xu XF, et al. In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system. Int J Nanomedicine. 2010;5:487-97.
50. Pulsinelli WA, Brierley JB. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke. 1979;10:267-72.
51. Hu X, Xie C, He S, Zhang Y, Li Y, Jiang L. Remifentanil postconditioning improves global cerebral ischemia induced spatial learning and memory deficit in rats via inhibition of neuronal apoptosis through the PI3K signaling pathway. Neurol Sci. 2013;34:1955-62.
52. Zhang R, Yang G, Wang Q, Guo F, Wang H. Acylated ghrelin protects hippocampal neurons in pilocarpine-induced seizures of immature rats by inhibiting cell apoptosis. Mol Biol Rep. 2013;40:51-8.
53. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
54. Morris R. Developments of a water-maze procedure form studying spatial learning in the rat. J Neurosci Methods. 1984;11:47-60.
55. Goldlust EJ, Paczynski RP, He YY, Hsu CY, Goldberg MP. Automated measurement of infarct size with scanned images of triphenyltetrazolium chloride-stained rat brains. Stroke. 1996;27:1657-62.
56. Zhang W, Miao Y, Zhou S, Jiang J, Luo Q, Qiu Y. Neuroprotective effects of ischemic postconditioning on global brain ischemia in rats through upregulation of hippocampal glutamine synthetase. J Clin Neurosci. 2011;18:685-9.
57. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic; 2007.
58. Habauzit V, Morand C. Evidence for a protective effect of polyphenols-containing foods on cardiovascular health: An update for clinicians. Ther Adv Chronic Dis. 2011;3:87-106.
59. Hassanzadeh P, Atyabi F, Dinarvand R. Resvertrol: more than a phytochemical. Biomed Rev. 2015;26:13-21.
60. Hassanzadeh P, Arbabi E, Atyabi F, Dinarvand R. The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders. Psychopharmacology. 2016;233:1087-96.
61. Manach C, Williamson G, Morand G, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nut. 2005;81:230S-42S.
62. Siekmann B, Westesen K. Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Colloids Surf B: Biointerfaces. 1994;3:159-75.
63. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol. 1990;186:421-31.
64. Spitz DR, Sullivan SJ, Malcolm RR, Roberts RJ. Glutathione dependent metabolism and detoxification of 4-hydroxy-2-nonenal. Free Radic Biol Med. 1991;11:415-23.
65. Warner DS, Sheng H, Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol. 2004;207:3221-31.
66. Michiels C, Raes M, Toussaint O, Remacle J. Importance of glutathione peroxidase, catalase, and cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med. 1994;17:235-48.
67. Chopra K, Tiwari V, Arora V, Kuhad A. Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy. J Pain. 2010;11:950-7.
68. Schmidt-Kastner R, Freund TF. Selective vulnerability of the hippocampus in brain ischemia. Neuroscience. 1991;4:599-636.
69. White BC, Sullivan JM, DeGracia DJ, O'Neil BJ, Neumar RW, Grossman LI, et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci. 2000;179:1-33.
70. Cui K, Luo X, Xu K, Murthy MRV. Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Prog NeuroPsychopharm Biol Psych. 2004;28:771-99.
71. Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm. 2016;109:224-35.
72. Balguri SP, Adelli GR, Janga KY, Bhagav P, Majumdar S. Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: effect of molecular weight and density of poly (ethylene) glycol. Int J Pharm. 2017;529:32-43.